Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Oncolytics Biotech Accelerates REO 033 Clinical Trial Enrollment | WAPE

FilingSEC EDGAR8-K

Oncolytics Biotech Accelerates REO 033 Clinical Trial Enrollment

Sep 28, 2026, 09:32 ET · SEC accepted

Filing content

The company has activated nearly all clinical sites for the REO 033 study and expects to report interim data by year-end 2026.

AI summary of the filing. Please also check the source.

Related companies

ONCOLYTICS BIOTECH INCONCYView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…